Tech Company Financing Transactions
Tarsus Pharmaceuticals Funding Round
Tarsus Pharmaceuticals, based in Irvine, secured $60 million from Vivo Capital, Aperture Venture Partners and Flying L Partners.
Transaction Overview
Company Name
Announced On
1/9/2020
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
Tarsus will use the funds to initiate a Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis and fuel Phase 1 and 2 development of other clinical programs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
19782 MacArthur Blvd. 285
Irvine, CA 92612
USA
Irvine, CA 92612
USA
Phone
Website
Email Address
Overview
Tarsus (Nasdaq: TARS) is a biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Ackermann
Chief Executive Officer
Bobby Azamian
VP - Marketing
Maaza Martin
VP - Regulatory Affairs
Stephanie Baba
VP - Regulatory Affairs
Mark Holdbrook
Browse more venture capital transactions:
Prev: 1/9/2020: Legalpad venture capital transaction
Next: 1/9/2020: Pieces Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs